{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:03:16Z","timestamp":1778601796905,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Soc Psychiatry Psychiatr Epidemiol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Severe mental illness may affect health behaviors and outcomes during pandemics. Few studies have assessed whether people living with schizophrenia spectrum disorders (SSD) experienced adverse COVID-19 outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In a population-based historical cohort study comprising members of a health maintenance organization, we included 1273 patients with SSD and 12,730 age- and sex-matched controls tested for SARS-CoV-2 between March 2020 and May 2022. We assessed the association between schizophrenia and hospitalization, hospital length-of-stay, 30-day, and one-year mortality, constructing multiple linear regression and logistic regression models adjusting for sociodemographic factors, BMI, smoking, number of comorbidities, and vaccinations. We also assessed whether vaccination modified the association between schizophrenia and mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among patients with SSD, 477 (37.5%) had a positive test, compared to 6203 (48.7%) in the comparison group. patients with SSD were at increased risk of hospitalization (adjusted odds ratio (OR<jats:sub>adj<\/jats:sub>) 3.44, 95% confidence interval (CI): 2.88\u20134.11, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001); longer length-of-stay (\u03b2\u2009=\u20091.20, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001); increased 30-day (OR<jats:sub>adj<\/jats:sub> 9.07, 95%CI 3.11\u201326.44); and one-year mortality (OR<jats:sub>adj<\/jats:sub> 6.27, 95%CI: 2.73\u201314.39). Further adjustment for vaccination altered the OR for 30-day mortality (OR<jats:sub>adj<\/jats:sub> 4.54, 95%CI: 1.54\u201313.38). Additionally, the association between schizophrenia and 30-day mortality was attenuated in strata of vaccinated (OR 4.79, 95%CI: 0.82\u201328.13, <jats:italic>p<\/jats:italic>\u2009=\u20090.082), vs. unvaccinated individuals (OR 7.53, 95%CI 2.19\u201325.92, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In our cohort, patients with SSD experienced a significantly higher rate of hospitalization, length of stay, and mortality following a positive SARS-CoV-2 test, even after adjusting for important prognostic factors. COVID-19 vaccination modified these risks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00127-025-02860-0","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T10:52:07Z","timestamp":1740999127000},"page":"2013-2022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long term outcomes after COVID-19 in patients with schizophrenia: a historical cohort study in a health maintenance organization"],"prefix":"10.1007","volume":"60","author":[{"given":"Gashaw Getaneh","family":"Dagnaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ora","family":"Paltiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asher","family":"Shafrir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2860_CR1","doi-asserted-by":"crossref","unstructured":"Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA - J Am Med Association. 323(20)","DOI":"10.1001\/jama.2020.6775"},{"key":"2860_CR2","unstructured":"Fond G, Llorca PM, Lan\u00e7on C, Auquier P, Boyer L (2021) Mortality in schizophrenia: towards a new health scandal? COVID-19 and schizophrenia. Ann Med Psychol (Paris). 179(4)"},{"issue":"4","key":"2860_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","volume":"4","author":"C Hjorth\u00f8j","year":"2017","unstructured":"Hjorth\u00f8j C, St\u00fcrup AE, McGrath JJ, Nordentoft M (2017) Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 4(4):295\u2013301","journal-title":"Lancet Psychiatry"},{"key":"2860_CR4","doi-asserted-by":"crossref","unstructured":"Taquet M, Luciano S, Geddes JR, Harrison PJ (2021) Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62\u2008354 COVID-19 cases in the USA. Lancet Psychiatry. 8(2)","DOI":"10.1016\/S2215-0366(20)30462-4"},{"key":"2860_CR5","doi-asserted-by":"crossref","unstructured":"Hassan L, Peek N, Lovell K, Carvalho AF, Solmi M, Stubbs B et al (2022) Disparities in COVID-19 infection, hospitalisation and death in people with schizophrenia, bipolar disorder, and major depressive disorder: a cohort study of the UK Biobank. Mol Psychiatry. 27(2)","DOI":"10.1038\/s41380-021-01344-2"},{"key":"2860_CR6","unstructured":"UNICEF https:\/\/www.unicef.org\/coronavirus\/what-we-know-about-omicron-variant. Accessed on 29\/04\/2023."},{"key":"2860_CR7","doi-asserted-by":"crossref","unstructured":"Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY et al (2020) Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 7(12)","DOI":"10.1016\/S2215-0366(20)30421-1"},{"key":"2860_CR8","doi-asserted-by":"crossref","unstructured":"Wang QQ, Xu R, Volkow ND (2021) Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 20(1)","DOI":"10.1002\/wps.20806"},{"key":"2860_CR9","doi-asserted-by":"crossref","unstructured":"Tzur Bitan D, Kridin K, Cohen AD, Weinstein O (2021) COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study. Lancet Psychiatry. 8(10)","DOI":"10.1016\/S2215-0366(21)00256-X"},{"key":"2860_CR10","doi-asserted-by":"crossref","unstructured":"Pardamean E, Roan W, Iskandar KTA, Prayangga R, Hariyanto TI (2022) Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: a systematic review, meta-analysis and meta-regression. 75, Gen Hosp Psychiatry","DOI":"10.1016\/j.genhosppsych.2022.01.010"},{"key":"2860_CR11","doi-asserted-by":"crossref","unstructured":"Li L, Li F, Fortunati F, Krystal JH (2020) Association of a prior Psychiatric diagnosis with mortality among hospitalized patients with Coronavirus Disease 2019 (COVID-19) infection. JAMA Netw Open. 3(9)","DOI":"10.1001\/jamanetworkopen.2020.23282"},{"key":"2860_CR12","doi-asserted-by":"crossref","unstructured":"Fond G, Pauly V, Orleans V, Antonini F, Fabre C, Sanz M et al (2021) Increased in-hospital mortality from COVID-19 in patients with schizophrenia. Encephale. 197147(2)","DOI":"10.1016\/j.encep.2020.07.003"},{"key":"2860_CR13","doi-asserted-by":"crossref","unstructured":"Tzur Bitan D, Krieger I, Kridin K, Komantscher D, Scheinman Y, Weinstein O et al (2021) COVID-19 prevalence and mortality among schizophrenia patients: a large-scale retrospective cohort study. Schizophr Bull. 47(5)","DOI":"10.1093\/schbul\/sbab012"},{"key":"2860_CR14","doi-asserted-by":"crossref","unstructured":"Murphy KA, McGinty E, Daumit GL (2021) Outcomes after COVID-19 diagnosis for people with versus without serious mental illness. J Gen Intern Med. 36(SUPPL 1)","DOI":"10.1007\/s11606-020-05950-8"},{"key":"2860_CR15","doi-asserted-by":"publisher","unstructured":"Ermakov EA, Melamud MM, Buneva VN, Ivanova SA (2022) Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives. Front Psychiatry [Internet]. 13. Available from: https:\/\/www.frontiersin.org\/journals\/psychiatry\/articles\/https:\/\/doi.org\/10.3389\/fpsyt.2022.880568","DOI":"10.3389\/fpsyt.2022.880568"},{"key":"2860_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.10.004","volume":"66","author":"G Fico","year":"2023","unstructured":"Fico G, Isayeva U, De Prisco M, Oliva V, Sol\u00e8 B, Montejo L et al (2023) Psychotropic drug repurposing for COVID-19: a systematic review and Meta-analysis. Eur Neuropsychopharmacol 66:30\u201344","journal-title":"Eur Neuropsychopharmacol"},{"key":"2860_CR17","doi-asserted-by":"crossref","unstructured":"Abosi O, Lopes S, Schmitz S, Fiedorowicz JG (2018) Cardiometabolic effects of psychotropic medications. 36, Hormone Molecular Biology and Clinical Investigation","DOI":"10.1515\/hmbci-2017-0065"},{"key":"2860_CR18","unstructured":"Meuhedet HMO (2023) https:\/\/www.meuhedet.co.il\/en\/customer-information\/about-meuhedet\/. Accessed on 9 August"},{"key":"2860_CR19","doi-asserted-by":"crossref","unstructured":"Tzur Bitan1,2 D, Givon-Lavi N, Kridin K, Kaliner E, Krieger I, Dov Cohen A et al (2022) Severe breakthrough COVID-19 infections in vaccinated patients with schizophrenia in Israel. Vol. 21, World Psychiatry","DOI":"10.1002\/wps.21028"},{"key":"2860_CR20","doi-asserted-by":"crossref","unstructured":"Sidana A, Goel V, Kaur S (2021) Impact of the COVID-19 Pandemic on Psychiatric hospitalization in a Tertiary Care Hospital of Northern India. Prim Care Companion CNS Disorders. 23(3)","DOI":"10.4088\/PCC.21m02936"},{"key":"2860_CR21","unstructured":"Stein MB (2020) COVID-19: Psychiatric illness. UpToDate"},{"key":"2860_CR22","doi-asserted-by":"crossref","unstructured":"Fond G, Pauly V, Leone M, Llorca PM, Orleans V, Loundou A et al (2021) Disparities in Intensive Care Unit Admission and Mortality among patients with Schizophrenia and COVID-19: a National Cohort Study. Schizophr Bull. 47(3)","DOI":"10.1093\/schbul\/sbaa158"},{"key":"2860_CR23","doi-asserted-by":"crossref","unstructured":"Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J et al (2021) Association of Psychiatric Disorders with Mortality among patients with COVID-19. JAMA Psychiatry. 78(4)","DOI":"10.1001\/jamapsychiatry.2020.4442"},{"issue":"11","key":"2860_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1176\/appi.ajp.20220660","volume":"180","author":"L R\u00f8devand","year":"2023","unstructured":"R\u00f8devand L, Rahman Z, Hindley GFL, Smeland OB, Frei O, Tekin TF et al (2023) Characterizing the Shared Genetic underpinnings of Schizophrenia and Cardiovascular Disease Risk factors. Am J Psychiatry 180(11):815\u2013826","journal-title":"Am J Psychiatry"},{"key":"2860_CR25","unstructured":"https:\/\/www.nimh.nih.gov\/health\/statistics [Internet]. National Institute of Mental Health. Statistics. Updated January 2018"},{"key":"2860_CR26","doi-asserted-by":"crossref","unstructured":"Burgdorf KS, Trabjerg BB, Pedersen MG, Nissen J, Banasik K, Pedersen OB et al (2019) Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders. Brain Behav Immun. 79","DOI":"10.1016\/j.bbi.2019.01.026"},{"key":"2860_CR27","doi-asserted-by":"crossref","unstructured":"Rha MS, Reum Kim A, Shin EC (2021) SARS-CoV-2-specific T cell responses in patients with COVID-19 and unexposed individuals. Vol. 21, Immune Network","DOI":"10.4110\/in.2021.21.e2"},{"key":"2860_CR28","doi-asserted-by":"crossref","unstructured":"Chen Z, John Wherry E (2020) T cell responses in patients with COVID-19. Nat Rev Immunol. 20(9)","DOI":"10.1038\/s41577-020-0402-6"},{"key":"2860_CR29","doi-asserted-by":"crossref","unstructured":"M\u00fcller N (2018) Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 44(5)","DOI":"10.1093\/schbul\/sby024"},{"key":"2860_CR30","doi-asserted-by":"crossref","unstructured":"Hassan L, Sawyer C, Peek N, Lovell K, Carvalho AF, Solmi M et al (2023) Heightened COVID-19 mortality in people with severe Mental illness persists after vaccination: a Cohort Study of Greater Manchester residents. Schizophr Bull. 49(2)","DOI":"10.1093\/schbul\/sbac118"},{"key":"2860_CR31","doi-asserted-by":"crossref","unstructured":"Mazereel V, Van Assche K, Detraux J, De Hert M (2021) COVID-19 vaccination for people with severe mental illness: why, what, and how? 8, Lancet Psychiatry","DOI":"10.1016\/S2215-0366(20)30564-2"},{"key":"2860_CR32","doi-asserted-by":"crossref","unstructured":"Ge E, Li Y, Wu S, Candido E, Wei X (2021) Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study. PLoS ONE. 16(10 October).","DOI":"10.1371\/journal.pone.0258154"},{"key":"2860_CR33","doi-asserted-by":"crossref","unstructured":"Wasserman D, Iosue M, Wuestefeld A, Carli V (2020) Adaptation of evidence-based suicide prevention strategies during and after the COVID-19 pandemic. World Psychiatry. 19(3)","DOI":"10.1002\/wps.20801"},{"key":"2860_CR34","unstructured":"Israel Ministry of Health https:\/\/www.health.gov.il\/English\/Topics\/Mental_Health\/rehabilitation\/rehab_sub\/housing\/Pages\/default.aspx. Community Housing of Patients with Mental Illnesses"},{"key":"2860_CR35","doi-asserted-by":"crossref","unstructured":"Kodesh A, Goldshtein I, Gelkopf M, Goren I, Chodick G, Shalev V (2012) Epidemiology and comorbidity of severe mental illnesses in the community: findings from a computerized mental health registry in a large Israeli health organization. Soc Psychiatry Psychiatr Epidemiol. 47(11)","DOI":"10.1007\/s00127-012-0478-9"}],"container-title":["Social Psychiatry and Psychiatric Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00127-025-02860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00127-025-02860-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00127-025-02860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:09:53Z","timestamp":1757142593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00127-025-02860-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2860"],"URL":"https:\/\/doi.org\/10.1007\/s00127-025-02860-0","relation":{},"ISSN":["0933-7954","1433-9285"],"issn-type":[{"value":"0933-7954","type":"print"},{"value":"1433-9285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted after obtaining the ethical clearance from the research ethics committee (IPR) of Meuhedet HMO (approval no.: 02-24-08-20, 2 September 2020). Individual informed consent was not required as the study used de-identified data extracted from the HMO database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript for submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}